1 – 7 of 7
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Collagenous colitis in systemic sclerosis: an overlooked and treatable complication.
(
- Contribution to journal › Article
- 2010
-
Mark
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
(
- Contribution to journal › Article
- 2008
-
Mark
MQX-503, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud's phenomenon
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.622-622(
- Contribution to journal › Published meeting abstract
-
Mark
Comparison of responders and non-responders to MQX-503, a novel investigational topical nitroglycerin formulation, in treatment of scieroderma-related and non-scleroderma-related Raynaud'S phenomenon
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.822-822(
- Contribution to journal › Published meeting abstract
-
Mark
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial
(
- Contribution to journal › Article
-
Mark
Safety and tolerability of MQX-503, a novel investigational topical formulation of nitroglycerin for the treatment of Raynaud's phenomenon
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.821-821(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis - A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
(
- Contribution to journal › Article